Assertio (ASRT) said Wednesday it agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.
Under the terms of the deal, shareholders will receive $23.50 per share in cash, representing a 30.6% premium to the original agreement with Garda Therapeutics and 75.8% premium to Assertio's unaffected share price on March 20, the company said.
The transaction is expected to close in the second quarter of 2026, after which Assertio Holdings will be delisted from Nasdaq, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments